Shire has licensed from Giuliani SpA the exclusive rights to develop and commercialize LIALDA in the US, Canada, Pacific Rim, and Europe (excluding Italy). LIALDA is known as MEZAVANT XL(TM) in the UK and Ireland, and MEZAVANT(R) elsewhere outside of the US. Giuliani SpA retains the development and commercialization rights in Italy. Cosmo Pharmaceuticals SpA, Milan, developed the MMX technology.
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger, and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website:
For further information please contact:
Media Sarah McGee (GolinHarris) +1 312 729 4125
Matthew Cabrey (Shire) +1 484 595 8248
DDW is the largest international gathering of physicians, researchers
and academics in the fields of gastroenterology, hepatology, endoscop
|SOURCE Shire plc|
Copyright©2008 PR Newswire.
All rights reserved